120 Chapter 6 cohort (cohort 2 mg: 2.58±1.15, cohort 10 mg: 1.91±1.09, cohort 50 mg: 1.43±0.71; p=0.23, suppl Figure 3). [89Zr]Zr-DFO-avelumab dose 10 mg was selected for [89Zr]Zr-DFO-avelumab PET/CT imaging for the remaining 11 patients. [89Zr]Zr-DFO-avelumab PET/CT with optimal dose Overall, 15 patients were available for analyses on [89Zr]Zr-DFO-avelumab PET/CT with 10 mg dose avelumab. This includes one patient with stage IV and 14 with early-stage NSCLC. The accumulation of [89Zr]Zr-DFO-avelumab was measured for all 17 [18F]FDG positive and RECIST measurable tumor lesions (primary tumor, locoregional lymph node metastases and distant metastases). The [89Zr]Zr-DFO-avelumab uptake, lesion size and location of those lesions are displayed in Figure 4. Highest [89Zr]Zr-DFO-avelumab SUVpeak was detected in an adrenal gland lesion (SUVpeak=18.6) while lowest SUVpeak was detected in a lung lesion (SUVpeak = 1.4). The [ 89Zr]Zr-DFO-avelumab SUVpeak was not related to lesion size (Spearman ρ 0.389, p = 0.09). Figure 4. Overview of [89Zr]Zr-DFO-avelumab-uptake of all patients imaged with avelumab 10mg. In these patients, 17 [18F]FDG-positive RECIST-measurable lesions were detected. Lesions were distributed over lung (n=14), lymph node (n=1) and adrenal gland (n=2).
RkJQdWJsaXNoZXIy MTk4NDMw